Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Metadata
Title
Examination of Smad2 and Smad4 copy-number variations in skin cancers
Authors
Yong Shao
Jie Zhang
Richu Zhang
Jun Wan
Wei Zhang
Bo Yu
Publication date
01-02-2012
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 2/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0773-7

Other articles of this Issue 2/2012

Clinical and Translational Oncology 2/2012 Go to the issue

Educational Series / Red Series

Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations

Educational Series / Blue Series

Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research

Research Articles

JAK/STAT signal pathway activation promotes progression and survival of human oesophageal squamous cell carcinoma

Brief Research Articles

CYP2D6*4 allele and breast cancer risk: Is there any association?

Research Articles

Association of increased DNA methyltransferase expression with carcinogenesis and poor prognosis in pancreatic ductal adenocarcinoma

Research Articles

Interobserver variability in target volume delineation in postoperative radiochemotherapy for gastric cancer. A pilot prospective study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits